This report was recently updated on April 16 2024 with the latest and most recent
market numbers
Global Cancer Biological Therapy Market Size, Trends, and Analysis - Forecasts To 2026 By Product (Monoclonal Antibodies (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Vaccines (Preventive, Therapeutic), Cancer Growth Blockers (Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors), Blood Cell Growth Factors (Lenograstim, Filgrastim), Cytokines (Interferons, Interleukins)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Cancer biological therapy uses living and non-living substances as a form of treatment which are derived from living organisms or artificially derived variations. Cancer biological therapy includes the use of various cytokines like interferons and interleukins, monoclonal antibodies like naked monoclonal antibodies and bispecific monoclonal antibodies, and vaccines. The cancer biological therapy market is driven by the growing prevalence in the population, positive results from the use of biosimilars in cancer treatment, and the expiry of cancer drug patents. Cancer has become one of the leading causes of death across the world and people are becoming more aware of cancer and its treatment. Exposure to toxic substances that can accumulate in the body over time and lifestyle like the use of alcohol, tobacco, and drugs are some of the major causes of cancer. The cancer biological therapy market is also expected to grow due to the growing demand for targeted cancer treatment and preventive vaccines. The cancer biological treatment utilizes the body’s immune system to fight off cancer either directly or indirectly. Most cancer biological therapies involve the use of vaccines or bacteria to coheres the body’s immune system to actively mitigate the growth of cancer cells while some use antibodies to mitigate the growth of cancer cells through targeted therapies that attack only the cancer cells. The cancer biological therapy market is hampered by the high costs involved in cancer biological therapy and the various complications and side effects of cancer therapy.
Based on various cancer biological therapy products available, the cancer biological therapy market can be segmented into monoclonal antibodies, vaccines, cancer growth blockers, blood cell growth factors, and cytokines. The monoclonal antibodies segment is expected to hold the dominant share of the market during the forecast period. The monoclonal antibodies segment includes naked monoclonal antibodies, conjugated monoclonal antibodies, and bispecific monoclonal antibodies. Monoclonal antibodies hold the largest share of the market as they are capable of targeted treatment. Monoclonal antibodies can target specific proteins on the surface of cells which can therefore help in increasing the absorption capability of the medicine and improvise the treatment’s efficiency for addressing and treating cancer. The growing demand for biological therapy instead of conventional anti-cancer drugs has resulted in the dominance of this segment. The vaccine segment is expected to register the fastest growth rate during the forecast period. The vaccine segment includes both preventive vaccines and therapeutic vaccines. Growing demand for preventive cancer treatment is expected to increase the demand for vaccines during the forecast period. Positive results from other vaccines like human papilloma vaccines for HPV, hepatitis B vaccines, and other vaccines are expected to increase the demand for vaccines in the cancer biological therapy market. Therapeutic cancer vaccines can mitigate the growth of relapsed cancer that is not responding to radiation therapy and chemotherapy while also not responding to surgery. The use of vaccines is expected to increase during the forecast period as the preventive and therapeutic benefits of cancer vaccines are becoming more apparent.
Based on the distribution channel, the cancer biological therapy market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold the largest share of the market. Most cancer patients visit hospitals regularly to get health checkups and to treat complications. It is more convenient for patients to buy the products directly from hospital pharmacies than other retail pharmacies and online pharmacies. Hospital pharmacies also carry large stocks of various pharmaceuticals which has also led to the dominance of this segment. Most cancer biological therapy products are not available as over-the-counter medication. They require prescriptions as well as professional knowledge on their storage and use. Patients are more comfortable having medical professionals administer treatment than relying on others or themselves. The online pharmacy segment is expected to register the fastest growth rate during the forecast period. Online pharmacies have been growing in demand in recent years due to their ease of access and procurement. Online stores can provide various discounts on the products and are capable of serving users in remote locations.
The North American region is expected to hold the largest share of the cancer biological therapy market. The region has a large geriatric population and large incidences of cancer. Increasing spending on healthcare combined with the large demand for advanced treatment procedures has resulted in the dominance of this region in the global cancer biological therapy market. Technological advancements in cancer therapy and the various research and development initiatives undertaken by government and private entities have also contributed to the dominance of this segment. The APAC region is expected to witness the fastest growth rate during the forecast period. The APAC region has a large population of people with an increasing number of cancer patients. The APAC region is expected to see increased spending on healthcare facilities and research and development of new products which are expected to increase the demand for cancer biological therapy. Growing awareness of technological advancements in cancer therapy procedures is also expected to result in the growth of the cancer biological therapy market in the region.
Spectrum Pharmaceuticals, Inc., Bristol-Myers Squibb, Novartis International AG, F. Merck & Co., Inc., Amgen Inc., Hoffmann-La Roche AG, Celgene Corporation, Eli Lilly, GlaxoSmithKline, and Seattle Genetics, Inc., among others, are the major vendors competing in the cancer biological therapy market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Cancer Biological Therapy Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Product Type Overview
2.1.3 Distribution Channel Overview
2.1.4 End-User Overview
2.1.5 Regional Overview
Chapter 3 Cancer Biological Therapy Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 The increasing expenditure on R&D by government and private entities
3.3.1.2 The growing awareness of novel cancer biological therapies available in the market
3.3.2 Industry Challenges
3.3.2.1 Lack of Adequate Infrastructure and Lack of Skilled Labor
3.4 Prospective Growth Scenario
3.4.1 Product Type Growth Scenario
3.4.2 Distribution Channel Growth Scenario
3.4.3 End-User Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Cancer Biological Therapy Market, By Product Type
4.1 Product Type Outlook
4.2 Monoclonal Antibodies
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Vaccines
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Cancer Growth Blockers
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
4.5 Blood Cell Growth Factors
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
4.6 Cytokines
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Cancer Biological Therapy Market, By Distribution Channel
5.1 Distribution Channel Outlook
5.2 Hospital Pharmacies
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Retail Pharmacies
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 Online Pharmacies
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Cancer Biological Therapy Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Product Type, 2019-2026 (USD Million)
6.2.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.7.2 Market size, By Distribution Channel, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Product Type, 2019-2026 (USD Million)
6.5.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Product Type, 2019-2026 (USD Million)
6.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Product Type, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Distribution Channel, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Bristol-Myers Squibb
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 Spectrum Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Novartis International AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 F. Hoffmann-La Roche AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Merck & Co., Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Celgene Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 GlaxoSmithKline PLC
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Eli Lilly
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Amgen
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
The Global Cancer Biological Therapy Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Cancer Biological Therapy Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
